Renaissance Technologies
ADAP

Renaissance Technologies’s Adaptimmune Therapeutics ADAP Stock Holding History

Renaissance Technologies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,054,089
Closed -$527K – 3195
2025
Q3 		$527K Buy
4,054,089
+2,171,229
+115% +$298K ﹤0.01% 2766
2025
Q2 		$451K Buy
1,882,860
+69,000
+4% +$18.4K ﹤0.01% 2885
2025
Q1 		$357K Sell
1,813,860
-712,664
-28% -$369K ﹤0.01% 2861
2024
Q4 		$1.36M Buy
2,526,524
+869,949
+53% +$634K ﹤0.01% 2307
2024
Q3 		$1.57M Sell
1,656,575
-129,766
-7% -$147K ﹤0.01% 2168
2024
Q2 		$1.74M Buy
1,786,341
+394,566
+28% +$433K ﹤0.01% 1959
2024
Q1 		$2.2M Buy
1,391,775
+21,536
+2% +$26K ﹤0.01% 1972
2023
Q4 		$1.09M Buy
1,370,239
+342,379
+33% +$193K ﹤0.01% 2352
2023
Q3 		$802K Sell
1,027,860
-478,515
-32% -$402K ﹤0.01% 2448
2023
Q2 		$1.39M Buy
1,506,375
+1,323,675
+725% +$1.58M ﹤0.01% 2236
2023
Q1 		$199K Sell
182,700
-378,273
-67% -$586K ﹤0.01% 3282
2022
Q4 		$819K Sell
560,973
-5,259
-0.9% -$8.52K ﹤0.01% 2653
2022
Q3 		$609K Buy
566,232
+56,232
+11% +$103K ﹤0.01% 2809
2022
Q2 		$867K Sell
510,000
-449,703
-47% -$772K ﹤0.01% 2812
2022
Q1 		$1.98M Buy
959,703
+532,016
+124% +$1.44M ﹤0.01% 2242
2021
Q4 		$1.6M Buy
+427,687
New +$1.95M ﹤0.01% 2317
2021
Q3 		– Sell
-303,495
Closed -$1.29M – 3421
2021
Q2 		$1.29M Buy
303,495
+202,495
+200% +$983K ﹤0.01% 2528
2021
Q1 		$536K Sell
101,000
-791,095
-89% -$4.53M ﹤0.01% 2883
2020
Q4 		$4.81M Sell
892,095
-429,516
-32% -$2.33M 0.01% 1611
2020
Q3 		$10.5M Sell
1,321,611
-383,800
-23% -$3.36M 0.01% 1091
2020
Q2 		$17.1M Sell
1,705,411
-44,549
-3% -$280K 0.01% 914
2020
Q1 		$4.76M Buy
1,749,960
+284,817
+19% +$945K ﹤0.01% 1598
2019
Q4 		$1.76M Buy
1,465,143
+586,384
+67% +$625K ﹤0.01% 2382
2019
Q3 		$1.33M Buy
878,759
+381,659
+77% +$892K ﹤0.01% 2480
2019
Q2 		$2M Sell
497,100
-297,400
-37% -$1.21M ﹤0.01% 2329
2019
Q1 		$3.42M Buy
794,500
+168,200
+27% +$783K ﹤0.01% 2042
2018
Q4 		$3.6M Sell
626,300
-407,500
-39% -$3.01M ﹤0.01% 1934
2018
Q3 		$14M Sell
1,033,800
-268,307
-21% -$2.81M 0.01% 1136
2018
Q2 		$15.5M Sell
1,302,107
-3,893
-0.3% -$48.5K 0.02% 1093
2018
Q1 		$14.7M Buy
1,306,000
+312,000
+31% +$2.73M 0.02% 1128
2017
Q4 		$6.64M Sell
994,000
-161,100
-14% -$1.24M 0.01% 1631
2017
Q3 		$9.46M Buy
1,155,100
+85,800
+8% +$536K 0.01% 1364
2017
Q2 		$4.8M Buy
1,069,300
+288,500
+37% +$1.51M 0.01% 1741
2017
Q1 		$4.3M Buy
780,800
+335,700
+75% +$1.47M 0.01% 1780
2016
Q4 		$1.8M Buy
445,100
+116,400
+35% +$558K ﹤0.01% 2280
2016
Q3 		$2.32M Buy
328,700
+139,500
+74% +$1.06M ﹤0.01% 2101
2016
Q2 		$1.54M Buy
189,200
+76,000
+67% +$716K ﹤0.01% 2344
2016
Q1 		$920K Buy
113,200
+83,900
+286% +$686K ﹤0.01% 2637
2015
Q4 		$353K Buy
+29,300
New +$287K ﹤0.01% 2838

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies's ADAP Position: Q4 2025 in Review

Renaissance Technologies sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 4,054,089 shares — an estimated $527K sold.

Renaissance Technologies first reported a position in ADAP in Q4 2015 and held it in 39 quarters. The position peaked at $17.1M in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Renaissance Technologies reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 4,054,089 Adaptimmune Therapeutics shares in Q4 2025, an estimated $527K.
  • Renaissance Technologies first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 39 quarters.
  • Renaissance Technologies's Adaptimmune Therapeutics position peaked at $17.1M in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.